Shares last traded at $24.80 which is just a bit higher than the 50 day moving average which is $23.04 and which is marginally higher than the 200 day moving average of $22.95. The 50 day moving average was up by +7.66% whereas the 200 day moving average was up $1.85 or +8.04%. Trading volume for Editas Medicine, Inc. was 832K in the last trading session. Overall, volume was down 19.21% under the stocks normal daily volume.
Investors are more bearish on shares of the company recently considering the change in short interest. The firm recorded a rise in short interest between September 29, 2017 and October 13, 2017 of 1.42%. Short shares grew 83,376 over that timeframe. Days to cover decreased from 4.0 to 4.0 and the percentage of shorted shares was 0.15% on October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (EDIT). Bank Of Montreal /can/ downsized its investment by shedding 300 shares a decrease of 50.0%. Bank Of Montreal /can/ now controls 300 shares worth $7,000. The total value of its holdings decreased 30.0%. As of quarter end Nationwide Fund Advisors had disposed of a total of 547 shares trimming its holdings by 2.8%. The value of the company’s investment in Editas Medicine, Inc. went from $322,000 to $448,000 increasing 39.1% quarter to quarter.
Victory Capital Management Inc divested its position by selling 2,040 shares a decrease of 4.9% as of 09/30/2017. Victory Capital Management Inc owns 39,812 shares with a value of $956,000. The value of the position overall is up by 36.2%. Simplex Trading, LLC trimmed its stake by shedding 32,867 shares a decrease of 76.6% in the quarter. Simplex Trading, LLC claims 10,063 shares valued at $241,000. The total value of its holdings decreased 66.5%.
On July 14, 2017 SunTrust Robinson Humphrey began coverage of EDIT setting a rating of “Hold”. On July 18 analysts at Oppenheimer initiated coverage on the stock with a rating of “Perform”.
Equity analyst Barclays starting coverage on the stock by announcing an initial rating of “Overweight”.
As of the last earnings report the EPS was $-3.17 and is expected to be $-2.88 for the current year with 40,926,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.77 with next year’s EPS anticipated to be $-2.85.
Editas Medicine, Inc., launched on September 3, 2013, is a genome editing company. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. The Company is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Once the complex binds to the DNA sequence it was designed to recognize, the complex makes a specific cut in the DNA, ultimately triggering the cell’s DNA repair machinery to change the targeted sequence. The Business’s platform consists of four interrelated components: nuclease engineering, delivery, control and specificity, and directed editing..